Literature DB >> 24482232

Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells.

Shilpa S Dhar1, Hunain Alam, Na Li, Klaus W Wagner, Jimyung Chung, Yeo Won Ahn, Min Gyu Lee.   

Abstract

Dysregulated expression of histone methyltransferases and demethylases is an emerging epigenetic mechanism underlying cancer development and metastasis. We recently showed that the histone H3 lysine 36 (H3K36) demethylase KDM2A (also called FBXL11 and JHDM1A) is necessary for tumorigenic and metastatic capabilities of KDM2A-overexpressing non-small cell lung cancer (NSCLC) cells. Here, we report that KDM2A transcriptionally represses the histone deacetylase 3 (HDAC3) gene by removing methyl groups from dimethylated H3K36 at the HDAC3 promoter in KDM2A-overexpressing NSCLC cells. KDM2A depletion reduced expression levels of cell cycle-associated genes (e.g. CDK6) and cell invasion-related genes (e.g. NANOS1); these levels were rescued by ectopic expression of KDM2A but not its catalytic mutant. These genes were occupied and down-regulated by HDAC3. HDAC3 knockdown significantly recovered the proliferation and invasiveness of KDM2A-depleted NSCLC cells as well as the levels of CDK6 and NANOS1 expression in these cells. Similar to their previously reported functions in other cell types, CDK6 and NANOS1 were required for the proliferation and invasion, respectively, of KDM2A-overexpressing NSCLC cells. In a mouse xenograft model, HDAC3 depletion substantially restored the tumorigenic ability of KDM2A knockdown cells. These findings reveal a novel cancer-epigenetic pathway in which the antagonistic effect of KDM2A on HDAC3 expression releases cell cycle-associated genes and cell invasion-related genes from HDAC3 repression and indicate the importance of this pathway for tumorigenicity and invasiveness of KDM2A-overexpressing NSCLC cells.

Entities:  

Keywords:  Chromatin; Gene Regulation; Histone Modification; Lung Cancer; Transcription Repressor

Mesh:

Substances:

Year:  2014        PMID: 24482232      PMCID: PMC3953262          DOI: 10.1074/jbc.M113.521625

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 2.  Histone lysine methylation: a signature for chromatin function.

Authors:  Robert J Sims; Kenichi Nishioka; Danny Reinberg
Journal:  Trends Genet       Date:  2003-11       Impact factor: 11.639

Review 3.  The diverse functions of histone lysine methylation.

Authors:  Cyrus Martin; Yi Zhang
Journal:  Nat Rev Mol Cell Biol       Date:  2005-11       Impact factor: 94.444

4.  A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters.

Authors:  Serge Saxonov; Paul Berg; Douglas L Brutlag
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

5.  Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Vania Gelmetti; Francesco Marchesi; Andrea Viale; Lucia Altucci; Clara Nervi; Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

6.  Histone demethylation by a family of JmjC domain-containing proteins.

Authors:  Yu-ichi Tsukada; Jia Fang; Hediye Erdjument-Bromage; Maria E Warren; Christoph H Borchers; Paul Tempst; Yi Zhang
Journal:  Nature       Date:  2005-12-18       Impact factor: 49.962

Review 7.  The epigenetic progenitor origin of human cancer.

Authors:  Andrew P Feinberg; Rolf Ohlsson; Steven Henikoff
Journal:  Nat Rev Genet       Date:  2006-01       Impact factor: 53.242

8.  Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line.

Authors:  K Nakano; T Mizuno; Y Sowa; T Orita; T Yoshino; Y Okuyama; T Fujita; N Ohtani-Fujita; Y Matsukawa; T Tokino; H Yamagishi; T Oka; H Nomura; T Sakai
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

9.  The histone deacetylase-3 complex contains nuclear receptor corepressors.

Authors:  Y D Wen; V Perissi; L M Staszewski; W M Yang; A Krones; C K Glass; M G Rosenfeld; E Seto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

10.  Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.

Authors:  Andrew J Wilson; Do-Sun Byun; Natalia Popova; Lucas B Murray; Kaitlin L'Italien; Yoshihiro Sowa; Diego Arango; Anna Velcich; Leonard H Augenlicht; John M Mariadason
Journal:  J Biol Chem       Date:  2006-03-13       Impact factor: 5.157

View more
  23 in total

Review 1.  Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins.

Authors:  Nana Zheng; Zhiwei Wang; Wenyi Wei
Journal:  Int J Biochem Cell Biol       Date:  2016-02-06       Impact factor: 5.085

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 3.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

4.  A demethylation deficient isoform of the lysine demethylase KDM2A interacts with pericentromeric heterochromatin in an HP1a-dependent manner.

Authors:  Dijana Lađinović; Jitka Novotná; Soňa Jakšová; Ivan Raška; Tomáš Vacík
Journal:  Nucleus       Date:  2017-08-17       Impact factor: 4.197

Review 5.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 6.  Histone demethylase KDM2A: Biological functions and clinical values (Review).

Authors:  Lisheng Liu; Jiangnan Liu; Qinghai Lin
Journal:  Exp Ther Med       Date:  2021-05-04       Impact factor: 2.447

7.  JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis.

Authors:  Na Li; Shilpa S Dhar; Tsai-Yu Chen; Pu-Yeh Kan; Yongkun Wei; Jae-Hwan Kim; Chia-Hsin Chan; Hui-Kuan Lin; Mien-Chie Hung; Min Gyu Lee
Journal:  Cancer Res       Date:  2016-01-08       Impact factor: 12.701

8.  Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.

Authors:  Yufeng Huang; Yiqian Liu; Lijiang Yu; Jing Chen; Juan Hou; Lihua Cui; De Ma; Wangkun Lu
Journal:  Tumour Biol       Date:  2014-09-23

Review 9.  Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.

Authors:  Alice Pasini; Angelo Delmonte; Anna Tesei; Daniele Calistri; Emanuele Giordano
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

10.  Knockdown of KDM2A inhibits proliferation associated with TGF-β expression in HEK293T cell.

Authors:  Wen-Hao Xu; Da-Yan Liang; Qi Wang; Jinhua Shen; Qing-Hua Liu; Yong-Bo Peng
Journal:  Mol Cell Biochem       Date:  2019-01-02       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.